Canada markets closed

Defence Therapeutics Inc. (DTC.CN)

Canadian Sec - Canadian Sec Real Time Price. Currency in CAD
Add to watchlist
0.5400+0.0300 (+5.88%)
At close: 03:54PM EDT
Full screen
Previous Close0.5100
Open0.5300
Bid0.5300 x N/A
Ask0.5400 x N/A
Day's Range0.5100 - 0.5400
52 Week Range0.4800 - 3.0100
Volume58,500
Avg. Volume31,276
Market Cap24.59M
Beta (5Y Monthly)1.45
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Newsfile

    Defence's Corporate Updates, Arranges Financing

    Vancouver, British Columbia--(Newsfile Corp. - September 27, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radiopharmaceuticals and novel immune-oncology vaccines and drug delivery technologies, is pleased to give a corporate update and to announce a financing.The Company wishes to announce that Mr. Sebastien Plouffe, Defence's Founder and Director, is stepping back-in as the Chief Executive Of

  • Newsfile

    Defence Appoints New Interim Chief Executive Officer

    Vancouver, British Columbia--(Newsfile Corp. - August 30, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), announces that Kwin Grauer has been appointed interim Chief Executive Officer replacing Sébastien Plouffe as President and Chief Executive Officer. This change comes as the Company moves from the preclinical stage toward a clinical stage.Mr. Grauer joined the Board of Directors of the Company in December, 2022. He is a ...

  • Newsfile

    Defence Investigates the Application of the Accum Hydrogel Technology to Deliver GLP-1 in Order to Increase the Treatment Efficacy of Diabetes and Weight Loss

    Vancouver, British Columbia--(Newsfile Corp. - August 19, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to announce a project consisting of investigating the potential benefit of using the Accum® technology to increase the half-life and efficacity of the GLP-1 agonist as a treatment for obesity and related comorbidities (